RECRO PHARMA INC (REPH) Stock Income Statement
NASDAQ:REPH - Nasdaq - Common Stock
| 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 75.36M | 66.50M | 99.22M | 77.35M | 71.83M | |||
| Cost Of Goods | 55.54M | 54.13M | 50.98M | 43.16M | 38.19M | |||
| Gross Profit | 19.82M | 12.37M | 48.24M | 34.19M | 33.64M | |||
| Operating Expenses | 19.41M | 20.71M | 24.61M | 88.23M | 73.96M | |||
| Research and Development | N/A | 0.00 | 0.00 | 39.99M | 33.10M | |||
| Selling, General, and Administrative Expenses | 18.37M | 18.12M | 19.91M | 36.88M | 25.43M | |||
| Operating Income | 412.00K | -8.34M | 23.63M | -54.04M | -40.31M | |||
| Interest Income/Expense | -15.13M | -19.16M | -19.01M | -8.24M | -11.65M | |||
| Non Recurring Items | 3.35M | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -11.37M | -27.50M | 4.63M | -62.29M | -51.96M | |||
| Income Tax | 0.00 | 0.00 | 0.00 | 17.44M | -9.78M | |||
| Net Income | -11.37M | -27.50M | -18.63M | -79.72M | -50.08M | |||
| EBITDA | 7.98M | 200.00K | 32.03M | -46.19M | -32.87M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.26 | -1.16 | -0.83 | -3.89 | -2.63 | |||
| Non GAAP EPS | -0.31 | -1.15 | 0.20 | -2.49 | -1.99 | |||
| Statistics | ||||||||
| Gross Profit Margin | 26.30% | 18.60% | 48.62% | 44.20% | 46.83% | |||
| Profit Margin | -15.09% | -41.35% | -18.78% | -103.06% | -69.72% | |||
| Operating Profit Margin | 0.55% | -12.54% | 23.82% | -69.86% | -56.12% | |||
All data in USD